Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Sigvotatug Vedotin

Antibody-drug conjugate · Cytotoxic, directed at integrin beta-6 (ITGB6) · developed by Seagen, a wholly owned subsidiary of Pfizer

Phase 3 Most advanced trial
PFE Developer
1 Registered trials

What is Sigvotatug Vedotin?

Sigvotatug vedotin is an antibody-drug conjugate in which a humanized IgG1 antibody binds integrin beta-6 on tumor cells and delivers the microtubule-disrupting agent MMAE after internalization and linker cleavage. It is being studied in non-small cell lung cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Antibody-drug conjugate
Targets
integrin beta-6 (ITGB6), tubulin (secondary target)
Mechanism
Cytotoxic, directed at integrin beta-6 (ITGB6)
Pathways
microtubule polymerization inhibition, G2/M cell cycle arrest, apoptosis
Therapy area
Oncology
Developer
Seagen, a wholly owned subsidiary of Pfizer (PFE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
QX0ONY0O9T

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06758401 Phase 3 Non-Small Cell Lung Cancer Recruiting PFE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Carcinoma, Non-Small-Cell LungCarcinoma, Non-Small-Cell Lung (NSCLC)Non-Small Cell Lung Cancer

Other drugs acting on ITGB6

More from Seagen, a wholly owned subsidiary of Pfizer

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the PFE page.

Follow PFE, the company behind Sigvotatug Vedotin

See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PFE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.